Arbutus Biopharma Corp (ABUS)
2.71
+0.03
(+1.12%)
USD |
NASDAQ |
May 03, 16:00
2.715
0.00 (0.00%)
After-Hours: 20:00
Arbutus Biopharma Revenue (Quarterly): 2.145M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.145M |
| September 30, 2023 | 4.658M |
| June 30, 2023 | 4.651M |
| March 31, 2023 | 6.687M |
| December 31, 2022 | 6.245M |
| September 30, 2022 | 5.952M |
| June 30, 2022 | 14.24M |
| March 31, 2022 | 12.58M |
| December 31, 2021 | 3.206M |
| September 30, 2021 | 3.34M |
| June 30, 2021 | 2.329M |
| March 31, 2021 | 2.113M |
| December 31, 2020 | 2.386M |
| September 30, 2020 | 1.523M |
| June 30, 2020 | 1.514M |
| March 31, 2020 | 1.491M |
| December 31, 2019 | 1.618M |
| September 30, 2019 | 3.061M |
| June 30, 2019 | 0.653M |
| March 31, 2019 | 0.679M |
| December 31, 2018 | 1.678M |
| September 30, 2018 | 1.587M |
| June 30, 2018 | 1.244M |
| March 31, 2018 | 1.436M |
| December 31, 2017 | 2.534M |
| Date | Value |
|---|---|
| September 30, 2017 | 6.892M |
| June 30, 2017 | 1.039M |
| March 31, 2017 | 0.235M |
| December 31, 2016 | -0.195M |
| September 30, 2016 | 0.774M |
| June 30, 2016 | 0.309M |
| March 31, 2016 | 0.603M |
| December 31, 2015 | 11.09M |
| September 30, 2015 | 4.065M |
| June 30, 2015 | 3.44M |
| March 31, 2015 | 4.682M |
| December 31, 2014 | 4.35M |
| September 30, 2014 | 4.362M |
| June 30, 2014 | 1.811M |
| March 31, 2014 | 4.43M |
| December 31, 2013 | 7.527M |
| September 30, 2013 | 2.963M |
| June 30, 2013 | 2.844M |
| March 31, 2013 | 2.132M |
| December 31, 2012 | 3.709M |
| September 30, 2012 | 3.097M |
| June 30, 2012 | 3.559M |
| March 31, 2012 | 3.572M |
| December 31, 2011 | 4.369M |
| September 30, 2011 | 4.009M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.653M
Minimum
Jun 2019
14.24M
Maximum
Jun 2022
4.231M
Average
3.061M
Median
Sep 2019
Revenue (Quarterly) Benchmarks
| Moderna Inc | 167.00M |
| Pacira BioSciences Inc | 181.24M |
| Chimerix Inc | 0.004M |
| Karyopharm Therapeutics Inc | 33.75M |
| Corvus Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -19.31M |
| Total Expenses (Quarterly) | 22.66M |
| EPS Diluted (Quarterly) | -0.12 |
| Enterprise Value | 362.27M |
| Profit Margin (Quarterly) | -900.3% |
| Earnings Yield | -16.24% |
| Normalized Earnings Yield | -16.23 |